EGCG
Information
- Drug Name
- EGCG
- Description
- Entry(CIViC)
CIViC
[No Data.]
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| Epigallocatechin-3-gallate (EGCG) sensitizes melan... | IFNAR1 | IFNAR1 OVEREXPRESSION | Sensitivity | true | MMMP | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00981292 | Completed | Phase 4 | Effects of Epigallocatechin Gallate (EGCG) in Healthy, Young Adults | August 2009 | December 2009 |
| NCT03978052 | Completed | N/A | Prevention of Cognitive Decline in ApoE4 Carriers With Subjective Cognitive Decline After EGCG and a Multimodal Intervention | October 30, 2019 | June 28, 2023 |
| NCT05039983 | Completed | Phase 1 | Study of Epigallocatechin-3-gallate (EGCG) for Supportive and Symptomatic Management in Patients With Esophageal Cancer | August 20, 2021 | January 2, 2024 |
| NCT00611416 | Completed | N/A | The Role of Tea Catechins and Caffeine in Relation to Energy Metabolism | November 2005 | February 2006 |
| NCT01662232 | Completed | N/A | Improvement of Endothelial Function by EGCG | August 2012 | September 2013 |
| NCT01855971 | Completed | Phase 2 | "Using Epigallocatechin Gallate (EGCG) and Cognitive Training to Modulate Cognitive Performance in Patients With Fragile X Syndrome" (TESFX) | June 11, 2013 | October 31, 2015 |
| NCT02731495 | Completed | Phase 2/Phase 3 | Effect of Epigallocatechin -3-gallate Supplementation in Traumatic Brain Injury Patients | March 2015 | January 2016 |
| NCT05758571 | Recruiting | Phase 1/Phase 2 | Oxygen Atomizing Inhalation of EGCG in the Treatment Interstitial Pneumonia in Cancer Patients | January 5, 2023 | December 31, 2025 |
| NCT02577393 | Unknown status | Phase 2 | Study of Epigallocatechin-3-gallate (EGCG) for Esophagus Protection in Patients With Lung Cancer Receiving Radial Radiotherapy | April 2015 | August 2022 |
| NCT01481818 | Unknown status | Phase 1/Phase 2 | Study of Topically Applied Green Tea Extract for Radio Dermatitis and Radiation Mucositis | September 2011 | August 2022 |
| NCT02580279 | Unknown status | Phase 2 | Study of Epigallocatechin-3-gallate (EGCG) for Skin Prevention in Patients With Breast Cancer Receiving Adjuvant Radiotherapy | December 2014 | October 2019 |
| NCT00434499 | Withdrawn | Phase 2 | Effect of EGCG on the Body's Response to Insulin | February 2007 | December 2015 |